Iain Mackay, Chief Financial Officer, to retire from GSK, Julie Brown appointed as successor

GSK plc (LSE/NYSE: GSK) today announced that Iain Mackay, Chief Financial Officer (CFO), has decided to retire from GSK.

The Board has agreed that he will step down as CFO and as an Executive Director of the Board in May 2023.

The Board has selected Ms Julie Brown, currently Chief Operating and Financial Officer, Burberry Group plc, as successor to Iain. Julie is a highly respected CFO with extensive experience in the biopharma and medtech sectors, having previously worked at AstraZeneca plc and Smith & Nephew plc and as a non-executive director and Audit Chair of Roche Holding AG.

Julie will join GSK in April 2023 and will work with Iain to transition responsibilities, taking responsibility as CFO and as an Executive Director of GSK on 1 May 2023.

Emma Walmsley, Chief Executive Officer, GSK, said: 'I want to thank Iain for all he's done for GSK, and for his leadership and support to our people. He has played a very significant role to help deliver the reshaping of GSK and to improve our operating and financial performance. I am absolutely delighted that Julie will be joining the leadership team as his successor. Julie is a highly experienced CFO with a tremendous understanding of the biopharma sector. We also share a strong passion for people development, diversity, inclusion and sustainability. I am looking forward to working together to deliver progress for patients, shareholders and our people.'

Jonathan Symonds, Chair, GSK, said: 'On behalf of the Board I would like to thank Iain for his significant contribution at GSK. He has been a highly valued member of the Board and has provided strong support to Emma and the management team. We are delighted that Julie will join the Board as Iain's successor. She is a CFO of exceptional calibre and experience and I look forward to the contribution she will make.'

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK's Q2 Results for 2022 and any impacts of the COVID-19 pandemic.

Contact:

Tel: [phone]

Email: [e-mail]

(C) 2022 Electronic News Publishing, source ENP Newswire